Lyrica
- Product NDC
- 63539-014
- Requested package NDC
- 63539-014-90
- 11-digit product format
- 635390014
- Labeler code
- 63539
- Product ID
- 63539-014_bfdec19d-6a54-449c-95b4-908d28e5369a
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- PREGABALIN
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- U.S. Pharmaceuticals
- Application
- NDA021446
- Marketing category
- NDA
- Marketing start
- 2004-12-30
- Marketing end
- 0000-00-00
- Substance
- PREGABALIN
- Active strength
- 75 mg/1
- DEA schedule
- CV
- NDC exclude flag
- No
- Listing certified through
- 2022-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 63539-014 | 63539-014-90 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021446-001 | LYRICA | PREGABALIN | 25MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-002 | LYRICA | PREGABALIN | 50MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-003 | LYRICA | PREGABALIN | 75MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-004 | LYRICA | PREGABALIN | 100MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-005 | LYRICA | PREGABALIN | 150MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-006 | LYRICA | PREGABALIN | 200MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-007 | LYRICA | PREGABALIN | 225MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 |
| N021446-008 | LYRICA | PREGABALIN | 300MG | CAPSULE / ORAL | AB | RLD, RS | 2004-12-30 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021446-001 | AB |
| N021446-002 | AB |
| N021446-003 | AB |
| N021446-004 | AB |
| N021446-005 | AB |
| N021446-006 | AB |
| N021446-007 | AB |
| N021446-008 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N021446-001 | LYRICA | 25MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-002 | LYRICA | 50MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-003 | LYRICA | 75MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-004 | LYRICA | 100MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-005 | LYRICA | 150MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-006 | LYRICA | 200MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-007 | LYRICA | 225MG | CAPSULE / ORAL | AB | RLD | 2004-12-30 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-008 | LYRICA | 300MG | CAPSULE / ORAL | AB | RLD, RS | 2004-12-30 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N021446-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-002 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-003 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-004 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-005 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-006 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-007 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N021446-008 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lyrica | PREGABALIN | Viatris Specialty LLC | d4734e7d-5079-455e-8ff5-8f4539c998a9 | 2025-04-15 | Warnings, Adverse reactions | 021446 NDA021446 |
| Lyrica | PREGABALIN | Parke-Davis Div of Pfizer Inc | 60185c88-ecfd-46f9-adb9-b97c6b00a553 | 2020-06-15 | Warnings, Adverse reactions | 021446 NDA021446 |
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 63539-014-90 | 63539001490 | 1 BLISTER PACK in 1 CARTON (63539-014-90) > 14 CAPSULE in 1 BLISTER PACK | 1 blister pack | 2004-12-30 | 0000-00-00 | No | No | Current |